Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot lung cancer early, avoiding unnecessary biopsies

NCT ID NCT07623473

Diagnosis Sponsor: Herlev and Gentofte Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

The NIMBLE study is testing whether blood-based biomarkers can accurately distinguish between cancerous and non-cancerous lung nodules. Researchers will analyze blood samples from 1,800 patients referred with a lung nodule, looking at protein markers, epigenetic smoking markers, and DNA changes. The goal is to improve lung cancer diagnosis and reduce the need for invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood tests (protein tumor markers, epigenetic smoking marker, fragmentome/mutational/methylome analysis of cell-free tumor DNA)
What this could lead to
If successful, this could lead to a simple blood test that helps doctors quickly tell whether a lung nodule is cancerous or not, reducing unnecessary invasive procedures.
What could go wrong
This is an observational study, not a treatment trial. The blood tests may not be accurate enough to replace current diagnostic methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients referred to the infiltrate unit at the Dept. of Pulmonology, Gentofte Hospital, Denmark

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit * Having signed informed consent Exclusion Criteria: * Active cancer, excluding non-melanoma skin cancer * Comorbidities that exclude the patient from clinical follow-up and final diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease lung cancer lung neoplasm pulmonary coin lesion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (diagnosis) Nodule solitary pulmonary

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gentofte Hospital

    RECRUITING

    Gentofte Municipality, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.